{"id":"W2403393996","doi":"10.1158/1538-7445.sabcs15-s5-07","title":"Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Breast cancer; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Progressive disease; Immunotherapy; Clinical trial; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006466883,0.0003536935,0.0007248562,0.0004878498,0.0001217267,0.00002044994,0.0002351656,0.0002041609,0.0009705994],"category_scores_gemma":[0.0001215365,0.0002422718,0.00008975551,0.0008939255,0.0008504353,0.0003,0.0001233924,0.0006045493,0.00001103072],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001714246,"about_ca_system_score_gemma":0.001035051,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004537976,"about_ca_topic_score_gemma":0.0006534737,"domain_scores_codex":[0.996532,0.0003123483,0.0006141003,0.0007729049,0.0009351256,0.0008335018],"domain_scores_gemma":[0.9976971,0.0007326727,0.000212209,0.000417321,0.0007036829,0.0002370697],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4765845,0.00102526,0.2721898,0.0002638688,0.0004743553,0.00005303873,0.00213472,0.00003021266,0.04485247,0.00001724255,0.0002724614,0.2021021],"study_design_scores_gemma":[0.04390439,0.002344282,0.9221922,0.004737682,0.00002994517,0.000006497681,0.0002947756,0.000004135147,0.02601561,0.00001527993,0.0001708843,0.0002843214],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992351,0.001709028,0.00000419056,0.001857566,0.00008823472,0.002524336,0.0007707496,0.00002049414,0.0006744082],"genre_scores_gemma":[0.9954197,0.003383763,0.00008240144,0.00008712957,0.00008313731,0.0004582952,0.00003591592,0.00006799999,0.0003816267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6500024,"threshold_uncertainty_score":0.9999427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01529012457989496,"score_gpt":0.3262191982827851,"score_spread":0.3109290737028901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}